Skip to content
OpenTrain AIFor AI Companies

HFEPX · Eval paper review

AG-JEPA: Anatomically Guided Joint Embedding Predictive Architecture for Neurodegenerative Representation Learning

Azad Singh, Ayantika Das, Amog Rao, Aiman Farooq +6 more

Published

Nov 13, 2026

Citations

0

Trust level

Low

Usefulness score

25/100 (Low)

Extraction confidence

45% (Low)

Derived from extracted protocol signals and abstract evidence.

Rater population

Not reported

Signals refreshed

Nov 13, 2026

Should you rely on this paper?

This paper is adjacent to HFEPX scope and is best used for background context, not as a primary protocol reference.

Use this as background context only. Do not make protocol decisions from this page alone.

Best use

Background context only

Use if you need

A secondary eval reference to pair with stronger protocol papers.

What to verify

Validate the evaluation procedure and quality controls in the full paper before operational use.

Main weakness

The available metadata is too thin to trust this as a primary source.

Human feedback signal
Not explicit
Not explicit in abstract metadata
Evaluation signal
Detected
Eval setup described
Usefulness for eval research
25/100
Adjacent candidate

Treat as adjacent context, not a core eval-method reference.

Abstract

Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent. However, during the transition from cognitively normal (CN) to mild cognitive impairment (MCI), the disease-related signals are often subtle and confined to only a few brain regions. Existing Joint Embedding Predictive Architecture (JEPA) models learn general structural representations but do not explicitly capture the anatomical regions affected in AD. We propose Anatomically Guided JEPA (AG-JEPA), which introduces anatomical tokens that interact with patch tokens during pretraining to learn region-specific representations from brain regions relevant to neurodegeneration. Building on this representation space, we further propose Prog-AG-JEPA, which models disease progression trajectory as a conditioned latent displacement within this space. We evaluate AG-JEPA across five downstream tasks spanning Alzheimer's disease diagnosis and progression prediction. AG-JEPA improves diagnosis and MCI prognosis, achieving an 8.4 percentage point AUROC gain over the strongest baseline on CN/MCI classification and a 7.1 percentage point gain on out-of-distribution CN/AD classification on the MR-RATE dataset, highlighting its effectiveness across both early-stage detection and cross-cohort generalization. For disease progression modeling, Prog-AG-JEPA consistently outperforms all baselines on future diagnosis and brain volume change prediction, demonstrating the value of anatomically grounded neurodegeneration representations for diagnosis and prognosis.

What we could verify

These are the protocol signals we could actually recover from the available paper metadata. Use them to decide whether this paper is worth deeper reading.

Human Feedback Types

missing

None explicit

No explicit feedback protocol extracted.

"Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent."

Evaluation Modes

partial

Automatic Metrics

Includes extracted eval setup.

"Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent."

Quality Controls

missing

Not reported

No explicit QC controls found.

"Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent."

Benchmarks / Datasets

missing

Not extracted

No benchmark anchors detected.

"Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent."

Reported Metrics

partial

Auroc

Useful for evaluation criteria comparison.

"AG-JEPA improves diagnosis and MCI prognosis, achieving an 8.4 percentage point AUROC gain over the strongest baseline on CN/MCI classification and a 7.1 percentage point gain on out-of-distribution CN/AD classification on the MR-RATE dataset, highlighting its effectiveness across both early-stage detection and cross-cohort generalization."

Benchmarks and datasets

No benchmark or dataset names were extracted from the available abstract.

Reported metrics

auroc
Human feedback details
Uses human feedback
No
Feedback types
None
Rater population
Not reported
Unit of annotation
Trajectory (inferred)
Expertise required
Medicine
Evaluation details
Evaluation modes
Automatic Metrics
Agentic eval
Long Horizon
Quality controls
Not reported
Evidence quality
Low
Use this page as
Background context only

Research brief

Metadata summary

Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent.

Based on abstract + metadata only. Check the source paper before making high-confidence protocol decisions.

Key takeaways

  • Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent.
  • However, during the transition from cognitively normal (CN) to mild cognitive impairment (MCI), the disease-related signals are often subtle and confined to only a few brain regions.
  • Existing Joint Embedding Predictive Architecture (JEPA) models learn general structural representations but do not explicitly capture the anatomical regions affected in AD.

Researcher actions

  • Compare this paper against nearby papers in the same arXiv category before using it for protocol decisions.
  • Check the full text for explicit evaluation design choices (raters, protocol, and metrics).
  • Use related-paper links to find stronger protocol-specific references.

Caveats

  • Generated from abstract + metadata only; no PDF parsing.
  • Signals below are heuristic and may miss details reported outside the abstract.

Recommended queries

Contribution summary

  • Brain MRI can reveal early signs of Alzheimers disease (AD) before measurable cognitive decline becomes apparent.
  • However, during the transition from cognitively normal (CN) to mild cognitive impairment (MCI), the disease-related signals are often subtle and confined to only a few brain regions.

Why it matters for eval

  • We evaluate AG-JEPA across five downstream tasks spanning Alzheimer's disease diagnosis and progression prediction.

Researcher checklist

  • Human feedback protocol is explicit

    No explicit human feedback protocol detected.

  • Evaluation mode is explicit

    Detected: Automatic Metrics

  • Quality control reporting appears

    No calibration/adjudication/IAA control explicitly detected.

  • Benchmark or dataset anchors are present

    No benchmark/dataset anchor extracted from abstract.

  • Metric reporting is present

    Detected: auroc